However, our most profitable tip of the year was Alizyme, the biotechnology company. We tipped the shares in February for 31.5p.
The price soared an astonishing 447 per cent (partly on the back of a licensing deal with a Japanese pharmaceutical company) and we advised readers to take profits in August after the price had soared to 172.5p.
In November we advised readers to buy back in after the shareshad slipped to 164p as rumours of a possible takeover bid began to circulate. The price has since climbed back to 171.75p.
Unfortunately, a number of other biotech companies we have tipped have lived up to the sector's reputation for deeply disappointment. Shares in Cambridge Antibody Technology, which we bought in January at 575p, fell 20 per cent over the year to finish at 460.25p.
The outlook for the company remains bleak pending a legal dispute with Abbott Laboratories over royalty payments for CAT's lead rheumatoid arthritis drug, Humira. It could be 18 months before the case is heard
Allianz Se stock quotes
Allianz Se stock charts
Follow this thread
